BioSpace News Archive

Nicox SA announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.

Valneva SE reported its consolidated financial results for the year ending December 31, 2023 and provided several key corporate updates.

So-Young International Inc. announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023.

ProVerum Limited announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a ‘stent-like’ expander designed to gently ‘open-up’ the obstructed urethra and alleviate the symptoms caused by BPH.

AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, announced the appointment of Jessica Stark, PhD, as a scientific advisor.

Zomedica Corp., a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Monday, April 1st, 2024, at 4:30 p.m. ET to discuss the Company’s operational and financial highlights for its fourth quarter and full year ended December 31, 2023.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced the sale of its distribution rights related to NIVIS Fibrillar Collagen Pack to Atlanta-based MiMedx Group, Inc.

Avid Bioservices, Inc. announced it received a notice on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250 as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024 in a timely manner.

Orchard Therapeutics today announced the details of its U.S. commercial launch of Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200.

ACELYRIN, INC today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.